Abstract
Alirocumab was the first drug registered by the US Drug Enforcement Agency (FDA) in the PCSK9 (subtilisin / kexin type 9 proprotein convertase) group (ACC, 2018). For daily clinical practice, parenteral subcutaneous injection is important.
For alirocumab as well as evolocumab, the interval is 1x every 2 weeks. The dose is 75 or 150 mg per 1 ml injection.
From a clinical point of view, its ability to reduce LDL-cholesterol levels by 50-60% and Lp(a) levels by 25-30% are the most significant. It also has a positive effect on other components of lipid metabolism.
It is very likely to have the potential to reduce cardiovascular risk. Alirocumab is used in patients at high and very high cardiovascular risk where the maximum tolerated dose of a statin with ezetimibe does not achieve LDL-cholesterol target levels.
It can also be used in patients with statin intolerance.